ArticleMethods in molecular biology (Clifton, N.J.)2025
Bioinspired Extracellular Vesicles for Enhanced Delivery of siRNA to Tumors.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles (LNPs) are among the most effective nanocarriers for siRNA delivery due to their high transfection efficiency, nucleic acid encapsulation capacity, and relatively low toxicity. This has led to significant interest from academic institutions and pharmaceutical companies. However, the intrinsic hepatic tropism of LNPs limits their potential for targeted siRNA delivery to tumors. Extracellular vesicles (EVs), as natural nucleic acid carriers, exhibit unique biological properties. In recent years, EVs derived from M1 macrophages have gained particular attention for tumor-targeted therapy. Bioinspired nanovesicles composed of LNPs and M1 macrophage-derived EVs may combine the advantageous characteristics of both carriers and offer a promising vehicle for siRNA delivery to tumor tissues, thus warranting further investigation. This chapter outlines a laboratory-scale method for constructing bioinspired nanovesicles. First, a range of experimental methods for screening and optimizing these nanovesicles are introduced. Then, various assessment metrics such as siRNA encapsulation efficiency, vesicle fusion efficiency, and target gene silencing efficiency are discussed. Finally, experimental designs are presented for evaluating the potential siRNA delivery capabilities of these bioinspired nanovesicles both in vitro and in vivo.
Indexed as
Identifiers
40877516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.